Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

New York, NY – August 7, 2024 - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Dr. Adrian Kilcoyne, M.D., MPH, MBA as its Chief Medical Officer, effective immediately. 

“We’re thrilled to welcome Dr. Kilcoyne to Cellectis. He is a strategic, forward-thinking drug developer who is passionate about delivering life-saving therapies to patients. His clinical vision and proven leadership, as well as his extensive experience, will strengthen our clinical development efforts as we advance our product pipeline of next-generation CAR T-cell therapies” said André Choulika, Ph.D., Chief Executive Officer at Cellectis.

Before joining Cellectis, Dr. Kilcoyne was Chief Medical Officer and Head of Research and Development at Celularity, advancing their oncology allogeneic CAR-T and NK Cell therapy programs. Prior to this, he was Chief Medical Officer at Humanigen. He has held numerous Oncology leadership roles across Research and Development, Medical Affairs, Commercial, Health Economic Outcome Research and Evidence Generation in both large pharmaceutical and biotechnology companies such as AstraZeneca and Celgene. Dr. Kilcoyne graduated from Trinity College, Dublin Medical School. He initially trained in Gynecological Oncology at the Hammersmith Hospital in London and subsequently in Public Health Medicine at Oxford during which time he completed a Master’s in Public Health. Dr. Kilcoyne then trained in pharmaceutical medicine and completed his MBA.

“I am excited to join Cellectis at this pivotal time for the company as it is poised to deliver on its mission to provide transformative UCART therapies to patients with significant unmet medical need,” said Dr. Adrian Kilcoyne. “I believe that Cellectis’ world-class capabilities in gene editing and cell therapy manufacturing, promising pipeline and experienced leadership team will enable us to accelerate our current clinical pipeline and drive future innovation as we strive to deliver first-in-class and best-in-class allogeneic cell and gene therapies.”

Dr. Mark Frattini departs Cellectis effective immediately to pursue other opportunities. We thank Dr. Frattini for his contributions and wish him well in his new endeavors.